Transfusion Strategy in Hematological Intensive Care Unit
NCT02461264 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 230
Last updated 2019-04-22
Summary
Patients with acute hematological disease (acute leukemia, aplastic anemia, hematopoietic stem cells autologous or allogeneic ...) and hospitalized in an intensive care unit hematology require compensation of anemia and thrombocytopenia by blood transfusions of red blood packed cells (RBP) or platelet concentrates (PC).The AFSSAPS (Agence Française de Sécurité Sanitaire des Produits de Santé) recommendations (2002) specify the need to transfuse 2 RBP in case of symptomatic anemia usually for a hemoglobin between 6 and 10 g / dL. These recommendations allow to transfuse a single RBP for very elderly patients or in cases of associated heart disease (heart failure). A recent development (2012) on post-transfusion pulmonary edema overload recommends transfusion unit by unit for high risk patients.
More recently, a Swiss team has historically compared transfusion policies in 2 139 patients with hematological malignancies. The first group received 2 RBP transfusion in case of symptomatic anemia or hemoglobin level \<6 g / dL. The other group only received 1 RBP at each transfusion. In total 2212 units in 1548 transfusions were performed and the 1 RBP transfusion policy has resulted in a 25% decrease in the number of RBP used without any complication. In a prospective single-center pilot study, we showed that transfusing a single RBP was possible without increasing the side effects of anemia, without complications and allow an overall reduction in consumption of red blood cell units.
Several meta-analyzes reported in intensive care or bleeding situations that a restrictive use of transfusions significantly reduces cardiac events, bleeding, bacterial infections and mortality. The number of patient to be treated to prevent one death is 33.
The main objective is to demonstrate in a randomized trial that the restrictive strategy (transfusion of a single unit at each transfusion) is not inferior to the liberal strategy (transfusion of 2 unit at each transfusion) in terms of severe complication. Transfusion are performed in case of hemoglobin level \<8g/dL.
Key secondary objectives are to reduce the number of RBP used and the cost of hospitalization with a comparison of complications/mortality in the 2 groups.
Conditions
- Transfusion Related Complication
Interventions
- DRUG
-
Single red blood packed cells Transfusion
- DRUG
-
Two packed red blood cells Transfusion
Sponsors & Collaborators
-
University Hospital, Caen
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-01-31
- Primary Completion
- 2019-06-30
- Completion
- 2019-09-30
Countries
- France
Study Locations
More Related Trials
-
Prophylactic DLI for the Prevention of Relapse Post HSCT in Patients With High Risk Myeloid Malignancy
NCT02856464 ·Status: UNKNOWN ·Phase: PHASE2
-
Transfusion Dependency at Diagnosis and Transfusion Intensity During Initial Chemotherapy Are Associated With Poorer Outcomes in Adult Acute Myeloid Leukaemia
NCT02844257 ·Status: COMPLETED
-
Timed-Sequential Induction in CBF-AML
NCT00428558 ·Status: COMPLETED ·Phase: PHASE3
-
Quality of Life-Guided Transfusion in Refractory MDS or AML
NCT07328191 ·Status: RECRUITING ·Phase: NA
-
INFUSION OF ALLOREACTIVE NATURAL KILLER (NK) CELLS AS CONSOLIDATION STRATEGY FOR ACUTE MYELOID LEUKEMIA PATIENTS
NCT03955848 ·Status: UNKNOWN ·Phase: NA
-
Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT00151242 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Randomised Prospective Comparison of the NMA Allograft and the Traditional Allograft in Acute Myeloid Leukaemia
NCT00224614 ·Status: UNKNOWN ·Phase: PHASE3
-
A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia
NCT02665143 ·Status: COMPLETED ·Phase: PHASE2
-
T-Cell Depleted Double UCB for Refractory AML
NCT01464359 ·Status: TERMINATED ·Phase: PHASE2
-
Multicenter Study of Risk-adapted Treatment for T-lineage ALL of Young Adults (18-59 Years Old)
NCT02619630 ·Status: RECRUITING ·Phase: PHASE2
-
Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia
NCT00004128 ·Status: UNKNOWN ·Phase: PHASE3
-
Efectiveness of Donor IL-15-stimulated NK Cells Post Transplant Infusion in in Acute Leukemia
NCT03669172 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Pre-emptive Immunomodulation After Allogeneic Stem Cell Transplantation in AML
NCT02888522 ·Status: UNKNOWN
-
Role of the Microparticles and of Tissue Factor in the Pro-thrombotic Phenotype and the Thromboembolic Complications During the Acute Lymphoblastic Leukemia in Children.
NCT02862652 ·Status: COMPLETED ·Phase: NA
-
Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia (2015)
NCT02428517 ·Status: TERMINATED
-
Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML
NCT04061239 ·Status: RECRUITING ·Phase: PHASE2
-
Impact of Remission Induction Chemotherapy Prior to Allogeneic SCT in Relapsed and Poor-response Patients With AML
NCT02461537 ·Status: COMPLETED ·Phase: PHASE3
-
Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission
NCT00002514 ·Status: COMPLETED ·Phase: PHASE3
-
Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL
NCT07059156 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)
NCT00961064 ·Status: COMPLETED ·Phase: PHASE2
-
Early Prophylactic Donor Lymphocyte Infusion After Allo-HSCT for Patients With AML
NCT03597321 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia
NCT05827549 ·Status: RECRUITING ·Phase: PHASE2
-
Carboplatin Plus Topotecan in Treating Patients With Relapsed Acute Myelogenous Leukemia
NCT00003255 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies
NCT04230265 ·Status: TERMINATED ·Phase: PHASE1
-
Use of Saline-Washed Platelet and Red Cell Transfusions in Adult Acute Leukemia
NCT01976442 ·Status: COMPLETED